News coverage about Scynexis (NASDAQ:SCYX) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Scynexis earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2722611629811 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- SCYNEXIS, Inc. (SCYX): Worth Watching Healthcare Stock: (stocksgeeks.com)
- SCYNEXIS, Inc. (SCYX) Sets 1 Year Low on Apr, 7 at $1.28 (styleonfleek365.com)
- SCYNEXIS, Inc. (SCYX) expected to touch -17.20% EPS growth for coming year (wallstreetinvestorplace.com)
- Scynexis (SCYX) Earns Buy Rating from Analysts at Guggenheim (americanbankingnews.com)
- Celgene (CELG) Buy Rating Maintained at RBC Capital; The TP Given is $120.0000; SCYNEXIS (SCYX)’s Sentiment Is … (mtastar.com)
SCYX stock traded up $0.02 during mid-day trading on Monday, reaching $1.30. 141,057 shares of the company traded hands, compared to its average volume of 380,793. The company has a current ratio of 4.43, a quick ratio of 4.43 and a debt-to-equity ratio of 0.48. Scynexis has a fifty-two week low of $1.23 and a fifty-two week high of $2.93.
In related news, CEO Marco Taglietti purchased 100,000 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was acquired at an average price of $1.69 per share, for a total transaction of $169,000.00. Following the purchase, the chief executive officer now owns 404,000 shares of the company’s stock, valued at $682,760. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have acquired a total of 141,500 shares of company stock valued at $237,155 in the last quarter. Company insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Scynexis (SCYX) Given News Sentiment Rating of 0.14” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3343785/scynexis-scyx-given-news-sentiment-rating-of-0-14.html.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Receive News & Ratings for Scynexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scynexis and related companies with MarketBeat.com's FREE daily email newsletter.